Robert L. Ferris, MD, PhD | Authors

September 16, 2021

The field is ripe for preventing the undesirable long-term effects of cancer treatment or reducing them altogether through de-intensification, according to Robert L. Ferris, MD, PhD.

July 03, 2021

It has taken some decades, but the identification of targets such as HER2 has enabled us to segregate cancers into different subtypes, develop novel therapeutic strategies, and eventually understand the biology distinguishing one group of patients from another, says Robert L. Ferris, MD, PhD.

May 12, 2021

One of the most exciting and successful historical demonstrations of translational immunotherapy is the development of monoclonal antibodies, says Robert L. Ferris, MD.

October 04, 2020

In the wake of the enthusiasm around cancer immunotherapy trial results—with several positive trials presented annually at each American Society of Clinical Oncology meeting in more and more diseases over several years—setbacks have served as a grim reminder that our work is not finished.

July 18, 2020

Exciting new knowledge and a more exquisite understanding of the role of tumor cell biology and the tumor microenvironment have driven the fields of precision oncology/genomics-based medicine and immuno-oncology/cancer immunotherapy.

June 19, 2020

"In all, these 3 exciting trials combining PD-1 or PD-L1 inhibition with targeted therapy, chemotherapy, or immune cell therapy bode well for evolving advances with this tolerable class of agents."